Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001641172-25-020611
Filing Date
2025-07-22
Accepted
2025-07-22 17:06:53
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A formdefa14a.htm DEFA14A 18486
2 GRAPHIC proxy_001.jpg GRAPHIC 2003290
3 GRAPHIC proxy_002.jpg GRAPHIC 2648840
  Complete submission text file 0001641172-25-020611.txt   6425932
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-13341 | Film No.: 251140927
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)